DOCSLIB.ORG

A Status Report on the Medical Management of Rosacea: Focus on Topical Therapies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Status Report on the Medical Management of Rosacea: Focus on Topical Therapies DRUG THERAPY TOPICS A Status Report on the Medical Management of Rosacea: Focus on Topical Therapies James Q. Del Rosso, DO osacea is a common inflammatory facial skin topical metronidazole, sulfacetamide 10%/sulfur 5%, disorder estimated to affect approximately and azelaic acid. R14 million people in the United States.1,2 About 57% of cases are diagnosed in patients younger than 50 years.3 Although the pathophysiology of What is the mechanism of rosacea has been somewhat elusive, multiple “flare action of topical metronidazole? factors” are well recognized, and associated racial and The mechanism of action of topical metronidazole is genetic predilections have been identified.1,4-7 Based not entirely clear.11 In vitro studies demonstrate inhi- on current understanding of the disease and recog- bition of inflammatory mediators generated by neu- nized clinical presentations, a standard classification trophils.14,15 Inhibition of neutrophil-generated of rosacea has been suggested.8 Therapy of rosacea reactive oxygen species and immunomodulator activ- has included both topical and systemic agents, with ity have been suggested.14-16 A systemic mechanism is treatment regimens selected primarily based on dis- not suspected because percutaneous absorption of ease severity.2 Due to the chronic nature of the dis- metronidazole is negligible.11 The effect of metro- order, long-term maintenance therapy and avoidance nidazole for rosacea is not believed to be associated of flare factors are necessary to reduce the frequency with antibacterial or antiparasitic activity.11,17,18 and severity of exacerbations.9-11 Topical metronidazole, available for clinical use since 1989, has been a “workhorse” of rosacea What have efficacy studies with treatment.2,11 Other commonly used topical thera- topical metronidazole demonstrated? pies established through formal studies and/or The efficacy of topical metronidazole has been estab- accepted clinical experience include sulfacetamide lished in 10 placebo-controlled studies encompassing 10%/sulfur 5%, clindamycin, and erythromycin.2,12 more than 500 patients with rosacea who were Most recently, azelaic acid has demonstrated effi- actively treated with metronidazole.11,19-28 The trials cacy for treatment of rosacea.13 Depending on the were randomized double-blinded studies in adult specific drug under discussion, various vehicle for- patients with inflammatory (stage 2) rosacea char- mulations exist. Overall, available studies demon- acterized by erythema, telangiectasia, papules, and strate efficacy with topical therapy. Efficacy is pustules. Study duration ranged from 7 to described as a significant reduction of inflamma- 12 weeks. Split-face comparisons were used in some tory lesion counts (papules, pustules) and a clini- studies.20,21 Topical metronidazole reduced papules cally evident decrease in erythema, with little to and pustules by 48% to 65%, with improvements no effect on established telangiectasias. The ranging from 20% to 50% greater than placebo. following review of rosacea therapy focuses on Reduction in erythema scores also has been demon- strated. Significant improvement for physician global From Las Vegas Skin & Cancer Clinics, Ltd, Nevada. assessment scores was consistently demonstrated in Dr. Del Rosso has served as a consultant and/or speaker for Allergan, the topical metronidazole treatment group. Local Inc; Berlex Laboratories; Dermik Laboratories, Inc; Galderma Laboratories, LP; and Medicis, The Dermatology Company. cutaneous reactions were reported to occur in up to Reprints: James Q. Del Rosso, DO, Las Vegas Skin & Cancer 2% of patients, and no significant noncutaneous reac- Clinics, Ltd, 4488 S Pecos Rd, Las Vegas, NV 89121. tions have been reported.11 VOLUME 70, NOVEMBER 2002 271 Drug Therapy Topics How long is an adequate twice daily (nϭ23) and metronidazole 1% cream trial with topical metronidazole? twice daily (nϭ42) versus tetracycline 250 mg 3 times Although many patients note significant benefit daily (nϭ50).33,34 The benefits of oral antibiotic ther- within the first month, patients should be apy are quicker onset of clinically evident response, encouraged to complete 8 to 12 weeks of therapy shorter time to peak efficacy, and improvement of ocu- before determining the extent of benefit related to lar rosacea. Potential disadvantages of oral antibiotic topical metronidazole.9,11 therapy are patient intolerance, potential adverse reactions, and long-term antibiotic exposure. What is the impact of drug concentration and application frequency on the efficacy and safety Do any studies support topical of topical metronidazole? metronidazole as maintenance therapy? Comparable efficacy has been documented with both In a 2-phase study, topical metronidazole was proven the 0.75% and 1% concentrations of topical metro- to be more effective than placebo in maintaining nidazole, even when used with the same frequency of remission in patients with rosacea.10 The first study application.11,29 A comparative investigator-blinded phase utilized oral tetracycline 250 mg 4 times daily study of metronidazole 0.75% (nϭ35) versus 1% in combination with metronidazole 0.75% gel (nϭ35) cream formulations applied once daily for applied twice daily for 12 weeks (nϭ113). Patients 12 weeks revealed no significant difference in efficacy, exhibiting at least 70% lesion reduction after the with comparable reductions in lesion counts and ery- first phase of the study were then eligible to progress thema.29 At study end point, the overall median per- to a blinded second phase of the study (maintenance centage change in lesion count and overall mean therapy). The maintenance therapy phase of the percentage change in erythema was Ϫ62% and study was completed during a 6-month period. Top- Ϫ26%, respectively, for the group treated with metro- ical metronidazole 0.75% gel twice daily (nϭ39) nidazole 0.75%, and Ϫ60% and Ϫ30%, respectively, was used in one patient group versus a second study for the metronidazole 1% study group. Both agents arm in which patients used a topical placebo vehicle were well-tolerated without significant differences (nϭ43). Topical metronidazole demonstrated statis- identified with regard to local adverse reactions. No tically significant superiority in maintaining remis- serious or systemic adverse reactions occurred. sion (77% vs 58%) and reducing lesion counts compared with placebo. Does the formulation vehicle of topical metronidazole impact on its efficacy? What is the role of topical The efficacy of topical metronidazole has been shown sulfacetamide 10%/sulfur 5%? to be comparable regardless of the vehicle/formulation The anti-inflammatory benefit of sulfacetamide used.11 Two studies in patients with moderate to severe 10%/sulfur 5% has been reported based on clinical rosacea treated twice daily for 12 weeks demonstrated experience and studies.12,35-37 Currently available comparable efficacy between metronidazole 0.75% gel preparations include “leave-on” topical suspension and 0.75% cream and metronidazole 0.75% gel and and lotion formulations and a skin cleanser. 0.75% lotion.30,31 No differences in efficacy were Although clinical efficacy and safety are estab- noted among any of the parameters evaluated, with lished, the mechanism of action of sulfacetamide reduction in inflammatory lesion counts serving as a 10%/sulfur 5% in rosacea is not fully understood. primary evaluation parameter in both studies. What have efficacy studies with topical How does topical metronidazole sulfacetamide 10%/sulfur 5% demonstrated? compare with oral antibiotic therapy? One open multicenter study was conducted to evalu- Data from 3 double-blind, double-dummy studies sug- ate the efficacy of a twice-daily application of gest that topical metronidazole produces efficacy com- sulfacetamide 10%/sulfur 5% lotion over an 8-week parable with low- to moderate-dose oral tetracycline treatment period (Nϭ54).35 Comparison with base- therapy.11,32-34 One 9-week study compared metronida- line revealed an 81% mean reduction in inflamma- zole 0.75% gel twice daily (nϭ12) with oxytetracy- tory lesion counts and a 43% mean reduction in cline 250 mg twice daily (nϭ15).32 Two 8-week erythema. This correlated with a 96% improvement studies included comparisons of metronidazole 1% in physician global evaluation and 94% improvement cream daily (nϭ25) versus oxytetracycline 250 mg in patient global evaluation. 272 CUTIS® Drug Therapy Topics A double-blind, 8-week study (Nϭ94) of neutrophil activity with inhibition of reactive oxygen sulfacetamide 10%/sulfur 5% lotion versus a placebo species may have relevance to the mechanism of vehicle also was conducted. The active therapy action of azelaic acid therapy for rosacea.42,43 group demonstrated a 65% decrease in inflammatory lesions by week 4 and a 78% reduction by week 8 versus a 44% decrease by week 4 and 36% reduction What have efficacy studies with by week 8 in the placebo vehicle group. The topical azelaic acid demonstrated? decrease in facial erythema reported in the actively Two double-blind studies have established the effi- treated study arm was 66% at week 4 and 83% at cacy and tolerability of azelaic acid 20% cream for week 8 compared with 33% at week 4 and 31% treatment of rosacea.13,43 A controlled, contralateral at week 8 in the placebo vehicle-treated group.12 split-face study (Nϭ33) of twice-daily application of An 8-week, investigator-blinded study compared azelaic acid 20% cream versus a placebo vehicle com- sulfacetamide 10%/sulfur 5% lotion
Load more

Recommended publications
  • Azelaic Acid
    Azelaic Acid (FINACEA) Topical Foam 15% National Drug Monograph August 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Azelaic acid is a naturally occurring C9-dicarboxylic acid that is found in plants Action (such as whole grain cereals), animals and humans. Azelaic acid has antiinflammatory, antioxidative and antikeratinizing effects. In rosacea skin, azelaic acid decreases cathelicidin levels and kallikrein 5 (KLK5) activity and possibly inhibits toll-like receptor 2 (TLR2) expression.1 A 15% gel formulation has been marketed for rosacea, and 20% cream has been available for acne vulgaris. The newer foam formulation consists of an oil- in-water emulsion and was designed to have a higher lipid content than the gel for dry and sensitive skin. Indication(s) Under Review Topical treatment of inflammatory papules and pustules of mild to moderate in This Document rosacea. Dosage Form(s) Under Foam, 15% Review REMS REMS No REMS Postmarketing Requirements See Other Considerations for additional REMS information Pregnancy Rating Category B Executive Summary Efficacy There have been no head-to-head trials comparing the foam and gel formulations of azelaic acid in terms of safety, tolerability and efficacy in the treatment of papulopustular (PP) rosacea.. In two major randomized clinical trials, azelaic acid foam produced small benefits over vehicle foam in achieving Investigator’s Global Assessment (IGA) treatment success (NNTs of 9.2 and 11.5) and in reducing inflammatory lesion counts.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Skin - Sulfa*Derm Sulfaderm Or Sulfa*Derm - Helps Promote Healthy Skin Function
    Skin - Sulfa*Derm Sulfaderm or Sulfa*Derm - Helps promote Healthy skin Function. Has been shown to help clear up most Acne in 24 hours, Bacterial infections, Rashes, Bed Sores, Dermatitis, Eczema, Fungus/Yeast, Psoriasis type problems, Ring Worm and Wounds that won't heal. HISTORY OF SULFUR Harnessing the power of volcanos, our cutting edge formula is considered a breakthrough for the treatment of acne. Sulfa*Derm has been shown to clear up acne in one day. The active ingredient sulfur from volcanic ash destroys bacteria quickly. The Zinc Oxide combats rashes. Tea Tree Oil is a well known antiseptic and anti-fungal, while the Aloe Vera re-nourishes the skin. Vitamin E is used as the base instead of oils that clog up the skin. Sulfa*Derm is probably the best acne and everything else cream that has ever been made. When treating skin problems it is recommended to detoxify your liver. Sulfur is a yellow mineral that quite often occurs in nature in powder form. It can, under pressure bond to water, as in mineral springs or mix into the earth, as in mud baths. Normally sulfur is expunged from under the ground through the craters of venting volcanoes, where it is spread around in chunky blocks. Sulfur has been around for a long time. Native Polynesians claim to have cured a variety of infections in their hot sulfur mineral springs. Russian mud treatments, high in sulfur, have been used for centuries as a reputed therapy for arthritis. California's Napa Valley, specifically the city called Sulfur Springs, was the health spa for the wealthy until the early 1900's.
    [Show full text]
  • Enhanced Catalytic Ozonation of Ibuprofen Using a 3D Structured
    www.nature.com/scientificreports OPEN Enhanced catalytic ozonation of ibuprofen using a 3D structured catalyst with MnO2 nanosheets on carbon microfbers Guhankumar Ponnusamy1, Hajar Farzaneh2, Yongfeng Tong1, Jenny Lawler1, Zhaoyang Liu1* & Jayaprakash Saththasivam1* Heterogeneous catalytic ozonation is an efective approach to degrade refractory organic pollutants in water. However, ozonation catalysts with combined merits of high activity, good reusability and low cost for practical industrial applications are still rare. This study aims to develop an efcient, stable and economic ozonation catalyst for the degradation of Ibuprofen, a pharmaceutical compound frequently detected as a refractory pollutant in treated wastewaters. The novel three-dimensional network-structured catalyst, comprising of δ-MnO2 nanosheets grown on woven carbon microfbers (MnO2 nanosheets/carbon microfber), was synthesized via a facile hydrothermal approach. Catalytic ozonation performance of Ibuprofen removal in water using the new catalyst proves a signifcant enhancement, where Ibuprofen removal efciency of close to 90% was achieved with a catalyst loading of 1% (w/v). In contrast, conventional ozonation was only able to achieve 65% removal efciency under the same operating condition. The enhanced performance with the new catalyst could be attributed to its signifcantly increased available surface active sites and improved mass transfer of reaction media, as a result of the special surface and structure properties of this new three- dimensional network-structured catalyst. Moreover, the new catalyst displays excellent stability and reusability for ibuprofen degradation over successive reaction cycles. The facile synthesis method and low-cost materials render the new catalyst high potential for industrial scaling up. With the combined advantages of high efciency, high stability, and low cost, this study sheds new light for industrial applications of ozonation catalysts.
    [Show full text]
  • Precipitated Sulfur: Summary Report
    Precipitated Sulfur: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Precipitated sulfur; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NoDerivatives 4.0 International Download date 02/10/2021 22:32:18 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12274 Summary Report Precipitated Sulfur Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • Hirsutism Joshua C
    Review Hirsutism Joshua C. Berkowitz, BA; Adeel Kahtri, MD; Rao N. Saladi, MD; Dovid Herskowitz, BA; Joshua L. Fox, MD Hirsutism is defined as the development of a malelike pattern of excess hair especially in women. Hirsut- ism often results from raised androgen levels in the body and may indicate the existence of a serious underlying endocrine condition, such as polycystic ovary syndrome (PCOS). Treatment of hirsutism may require both medical and cosmetic actions. Medical therapy aims to counteract any suspected hormonal imbalance and can include administration of oral contraceptives and antiandrogens. Cosmetic treat- ment directly addresses excess hair and seeks to either remove the hair or diminish its appearance. Cos- metic options range from conventional methods, such as shaving and waxing, to modern techniques, such as laserCOS photoepilation. DERM irsutism refers to the growth of coarse that occurs despite normal androgen levels and normal terminal hair in females that follows a ovulatory function. malelike pattern, most commonly in the To comprehend the underlying mechanism of hirsut- upper lip area, beard area, abdomen, or ism, it is necessary to understand the physiology of hair chest. The amount of hair that is consid- growth. There are 2 types of hair: fine, nonpigmented Hered Donormal is subjective. In someNot cultures, women are vellus hairCopy and coarse, pigmented terminal hair. Both of disturbed by even a small amount of excess hair, while these hair types originate from the same pilosebaceous in other cultures, larger amounts may be tolerated and unit in the skin. Development of terminal hair mainly considered normal. The perception of excess hair has an is dependent on stimulation of the pilosebaceous unit associated psychosocial stigma that affects the lives of by androgens.
    [Show full text]
  • Food and Drug Administration, HHS § 333.350
    Food and Drug Administration, HHS § 333.350 (b) References in this subpart to reg- § 333.350 Labeling of acne drug prod- ulatory sections of the Code of Federal ucts. Regulations are to chapter I of title 21 (a) Statement of identity. The labeling unless otherwise noted. of the product contains the established name of the drug, if any, and identifies § 333.303 Definitions. the product as an ‘‘acne medication,’’ As used in this subpart: ‘‘acne treatment,’’ ‘‘acne medication’’ (a) Acne. A disease involving the oil (insert dosage form, e.g., ‘‘cream,’’ glands and hair follicles of the skin ‘‘gel,’’ ‘‘lotion,’’ or ‘‘ointment’’), or which is manifested by blackheads, ‘‘acne treatment’’ (insert dosage form, whiteheads, acne pimples, and acne e.g., ‘‘cream,’’ ‘‘gel,’’ ‘‘lotion,’’ or blemishes. ‘‘ointment’’). (b) Acne blemish. A flaw in the skin (b) Indications. The labeling of the resulting from acne. product states, under the heading ‘‘In- (c) Acne drug product. A drug product dications,’’ the phrase listed in para- used to reduce the number of acne graph (b)(1) of this section and may blemishes, acne pimples, blackheads, contain any of the additional phrases and whiteheads. listed in paragraph (b)(2) of this sec- (d) Acne pimple. A small, prominent, tion. Other truthful and nonmisleading inflamed elevation of the skin result- statements, describing only the indica- ing from acne. tions for use that have been established (e) Blackhead. A condition of the skin and listed in paragraph (b) of this sec- that occurs in acne and is character- tion, may also be used, as provided in ized by a black tip.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Minocycline-Induced Pigmentation Mimicking Persistent Ecchymosis
    CONTINUING MEDICAL EDUCATION Minocycline-Induced Pigmentation Mimicking Persistent Ecchymosis Sherry Youssef, MD, MPH, MS; Kathy Kim Langevin, MD, MPH; Lorraine C. Young, MD RELEASE DATE: July 2009 TERMINATION DATE: July 2010 The estimated time to complete this activity is 1 hour. GOAL To understand minocycline-induced pigmentation to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, you will be able to: 1. Distinguish the 3 common patterns of pigmentation based on clinical characteristics. 2. Recognize histologic findings of pigmentation. 3. Discuss the role of the duration and cumulative dose of minocycline on the incidence of pigmentation. INTENDED AUDIENCE This CME activity is designed for dermatologists and general practitioners. CME Test and Instructions on page 40. This article has been peer reviewed and ap- HealthCom, Inc. Albert Einstein College of Medicine proved by Ranon Ephraim Mann, MD, Assistant is accredited by the ACCME to provide continuing Professor, Department of Medicine (Dermatology), medical education for physicians. Albert Einstein College of Medicine. Review date: Albert Einstein College of Medicine designates June 2009. this educational activity for a maximum of 1 AMA This activity has been planned and implemented PRA Category 1 Credit TM. Physicians should only in accordance with the Essential Areas and Policies claim credit commensurate with the extent of their of the Accreditation Council for Continuing participation in the activity. Medical Education through the joint sponsorship of This activity has been planned and produced in Albert Einstein College of Medicine and Quadrant accordance with ACCME Essentials. Drs. Youssef and Young report no conflict of interest. Dr.
    [Show full text]
  • Antibiotic and Antibiotic-Steroid Combination Drops and Ointments
    Clinical Policy: Ophthalmic Agents: Antibiotic and Antibiotic-Steroid Combination Drops and Ointments Reference Number: OH.PHAR.PPA.74 Effective Date: 01.20 Revision Log Last Review Date: 10.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description OPHTHALMIC AGENTS: ANTIBACTERIAL - QUINOLONES NO PA REQUIRED “PREFERRED” NON- PREFERRED “NON- PREFERRED” CILOXAN® ointment (ciprofloxacin) BESIVANCE® drops (besifloxacin) CIPROFLOXACIN drops (generic of Ciloxan®) GATIFLOXACIN drops (generic of Zymaxid®) MOXIFLOXACIN (generic for Vigamox®) LEVOFLOXACIN drops (generic of Quixin®) OFLOXACIN drops (generic of Ocuflox®) MOXEZA® drops (moxifloxacin) OPHTHALMIC AGENTS: ANTIBACTERIAL – NON-QUINOLONE NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” BACITRACIN-POLYMYXIN ointment AZASITE® drops (azithromycin) ERYTHROMYCIN ointment (generic of Ilotycin®) BACITRACIN ointment GENTAMICIN drops GENTAMICIN ointment NEOMYCIN/POLYMYXIN/ BACITRACIN ointment (generic of SULFACETAMIDE ointment ® Neosporin ) NEOMYCIN/POLYMYXIN/ GRAMICIDIN drops (generic of ® Neosporin ) ® POLYMYXIN/TRIMETHOPRIM drops (generic of Polytrim ) SULFACETAMIDE drops ® TOBRAMYCIN drops (generic of Tobrex ) TOBREX® ointment (tobramycin) OPHTHALMIC AGENTS: ANTIBACTERIAL – STEROID COMBINATIONS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” NEOMYCIN/POLYMYXIN/ BACITRACIN/ BLEPHAMIDE® drops, ointment HYDROCORTISONE ointment (prednisolone/sulfacetamide) NEOMYCIN/POLYMYXIN/ DEXAMETHASONE drops (generic
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Sulfonamides and Sulfonamide Combinations*
    Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials
    [Show full text]